{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-041082","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.565526+00:00","generated_at":"2026-05-17T10:14:30.362269+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BeOne sells IMDELLTRA ex-China royalty rights to Royalty Pharma for up to $950M","bullets":["Upfront payment of $885M; option to sell additional royalties within 12 months for up to $65M.","BeOne retains share of royalty on annual ex-China net sales above $1.5B and all other Amgen collaboration rights.","IMDELLTRA is a DLL3-targeting bispecific T-cell engager approved in US for ES-SCLC after platinum chemo.","Transaction expected to close shortly; proceeds provide operational and strategic flexibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-041082","json":"https://secwatch.observer/filing/0001628280-25-041082.json","markdown":"https://secwatch.observer/filing/0001628280-25-041082.md","text":"https://secwatch.observer/filing/0001628280-25-041082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000162828025041082/0001628280-25-041082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000162828025041082/bgne-20250825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:14:30.362269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f5e12580082d21316144ad8e58eafc93f6dbf97","claim":"BeOne Medicines Ltd. incurred debt of $885 million upfront payment, with option for up to $65 million additional with Royalty Pharma Investments 2023 ICAV maturing sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli.","evidence_excerpt":"(the “Company”), BeOne Medicines I GmbH (the “Seller”), a subsidiary of the Company, and Royalty Pharma Investments 2023 ICAV (“Royalty Pharma”) entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828025041082/0001628280-25-041082-index.htm","confidence":0.85,"family_label":"Debt Financings","details":[{"label":"Principal","value":"$885 million upfront payment, with option for up to $65 million additional"},{"label":"Counterparty","value":"Royalty Pharma Investments 2023 ICAV"},{"label":"Maturity","value":"sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}